1. Search Result

Search Result

Results for "1835667-12-3" in MCE Product Catalog:

Cat. No. Product Name Target Research Areas
  • HY-109189


    EGFR Cancer
    Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity.